I like it! Turkey is one of the six most important emerging markets for drugs (#msg-47908751), and this deal shows that AMGN wants in on the lucrative business of selling branded generics in emerging markets. As I’ve posted on this board ad nauseam (e.g. #msg-66847124, #msg-61960596) branded generics in emerging markets is the most important future growth driver of the drug/biotech industry.
As for AMGN’s purportedly losing biotech “cred” by buying a generic-drug company, so be it. I’ll take profits over biotech cred any day of the week.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”